Thomas M Kristie

US Patent:

20110144184, Jun 16, 2011

Filed:

Jul 23, 2009

Appl. No.:

13/055587

Inventors:

Thomas Kristie - Silver Spring MD, US
Yu Liang - Rockville MD, US

Assignee:

The United States of America, as rep. by the Secretary, Dept of HHS - Bethesda MD

International Classification:

A61K 31/7105
A61K 31/135
A61K 31/137
A61K 31/15
A61K 31/42
A61P 31/12
A61P 31/20
A61P 31/22

US Classification:

514 44 A, 514647, 514655, 514654, 514378

Abstract:

An embodiment of the invention provides preventing or treating a viral infection of a host, comprising administering to the host an effective amount of an inhibitor of the protein LSD1 and/or a monoamine oxidase inhibitor. Another embodiment of the invention provides preventing or treating reactivation of a virus after latency in a host, comprising administering to the host an effective amount of an inhibitor of the protein LSD1 and/or a monoamine oxidase inhibitor. Another embodiment of the invention provides preventing or treating a viral infection in a mammal that has undergone, is undergoing, or will undergo an organ or tissue transplant, comprising administering to the mammal an effective amount of an inhibitor of the protein LSD1 and/or a monoamine oxidase inhibitor before, during, and/or after the organ or tissue transplant. The viral infection may be due to a herpesvirus, such as herpes simplex virus type 1 (HSV-1) or type 2 (HSV-2), varicella zoster virus (VZV), or cytomegalovirus (CMV). The viral infection may also be due to an adenovirus, including types 1-5.